Savara Inc. (NASDAQ: SVRA) presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE